PET as a potential tool for imaging molecular mechanisms of oncology in man

Trends in Molecular Medicine

Volumn 7, Issue 10, 2001, Pages 442-446

  Price, Pat ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; COMBRETASTATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IODINE 124; TEMOZOLOMIDE; THYMIDYLATE SYNTHASE; WATER O 15;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CANCER STAGING; DRUG MECHANISM; DRUG RESPONSE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; NUCLEOSIDE TRANSPORT; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR BLOOD FLOW;

EID: 0034798179     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(01)02127-X     Document Type: Review

References (41)

1. The imaging science of positron emission tomography
2. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially respectable lung cancer
3. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer
4. Staging non-small cell lung cancer with whole-body PET
5. 18F-FDG imaging in breast cancer
6. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
7. Whole-body PET proves superior to CT for staging primary colorectal carcinoma
8. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
9. Use of fluorine-18 fluorodeoxy-glucose positron emission tomography in the detection of silent metastases from malignant melanoma
10. The value of positron emission tomography scanning in the detection of sub-clinical metastatic melanoma
11. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting
12. Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) in the diagnosis and preoperative staging of head and neck tumours: A prospective study
13. Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma
14. The role of positron emission tomography (PET) in the management of lymphoma patients
15. PET scanning in head and neck oncology: A review
16. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differential thyroid cancer: Preliminary results
17. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study
18. 18-FDG positron emission tomography of the pancreas: Diagnostic benefit in the follow-up of pancreatic carcinoma
19. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer
20. The role of PET-FDG in questionable diagnosis of relapse in the presence of radionecrosis of brain tumours
21. Contribution of nuclear medicine to the diagnosis of recurrent brain tumours and cerebral radionecrosis
22. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms
23. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas
24. Clinical FDG-PET in diagnosis and evaluation of radiation response of patients with nasopharyngeal tumour
25. 18F]fluorodeoxyglucose and positron emission tomography: A pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas
26. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG-PET
27. 18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
28. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
29. The role of positron emission tomography in occult primary head and neck cancers
30. Occult primary tumours of the head and neck: Detection with 2-[F-18]fluoro-2-deoxy-D-glucose SPECT
31. Regional methionine and glucose uptake in high-grade gliomas: A comparative study on Pet-guided stereotactic biopsy
32. Use of positron emission tomography (PET) in sterotactic conditions for brain biopsy
33. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumour benefit oncology?
34. 18-F]-fluorodeoxyglucose and positron emission tomography: Review and EORTC recommendations
35. The in vivo quantitation of thymidine salvage by positron emission tomography (PET) as a pharmacodynamic endpoint for thymidylate synthase (TS) inhibition
36. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In vivo imaging of drug action
37. Carbon-11-thymidine and FDG to measure therapy response
38. Measurement of tumour and normal tissue (NT) per fusion by positron emission tomography (PET) in the evaluation of antivascular therapy: Results in the phase I study of combretastatin A4 phosphate (CA4P)
39. 18F-labeled RGD-containing glycopeptide and positron emission tomography
40. Evaluation of in vivo mechanism of action of temozolomide
41. Quantification of target gene expression by imaging reporter gene expression in living animals